// App-Quantinova.ai

: A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Researchers

Presenter

  • Wilson I. Gonsalves

Principal Investigators

  • Natalia Neparidze

  • Jacob B. Allred

  • Shaji K Kumar

  • Joel M. Reid

  • Geoffrey Shapiro

  • Brian A. Costello

  • Richard Piekarz

  • Rachid C. Baz

  • Srinivas Devarakonda

Medical Centers

  • Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN

  • Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

  • Division of Hematology, Mayo Clinic, ROCHESTER, MN

  • Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD

  • Dana-Farber Cancer Institute, Boston

  • Department of Malignant Hematology, Moffitt cancer center and research institute, tampa, FL

  • Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT

  • Department of Oncology, Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved